NASDAQ:MOR MorphoSys (MOR) Stock Price, News & Analysis $18.96 0.00 (0.00%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$18.96▼$18.9650-Day Range$17.87▼$18.9652-Week Range$4.18▼$19.50VolumeN/AAverage Volume1.02 million shsMarket Capitalization$2.86 billionP/E RatioN/ADividend YieldN/APrice Target$11.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get MorphoSys alerts: Email Address MorphoSys MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside37.9% Downside$11.78 Price TargetShort InterestHealthy0.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.42) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.42 out of 5 starsMedical Sector900th out of 924 stocksPharmaceutical Preparations Industry418th out of 426 stocks 1.2 Analyst's Opinion Consensus RatingMorphoSys has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMorphoSys has received no research coverage in the past 90 days.Read more about MorphoSys' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.09% of the outstanding shares of MorphoSys have been sold short.Short Interest Ratio / Days to CoverMorphoSys has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MorphoSys has recently decreased by 48.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMorphoSys does not currently pay a dividend.Dividend GrowthMorphoSys does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MOR. Previous Next 1.9 News and Social Media Coverage News SentimentMorphoSys has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MorphoSys this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MorphoSys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.05% of the stock of MorphoSys is held by insiders.Percentage Held by InstitutionsOnly 18.38% of the stock of MorphoSys is held by institutions.Read more about MorphoSys' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MorphoSys are expected to grow in the coming year, from ($2.42) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MorphoSys is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MorphoSys is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphoSys has a P/B Ratio of 54.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MorphoSys' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Preserve GoldTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?Click here to get your complimentary retirement guide! About MorphoSys Stock (NASDAQ:MOR)MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOR Stock News HeadlinesAugust 18, 2024 | finance.yahoo.comMORF Apr 2025 62.500 call(CONTR (MORF250417C00062500)August 15, 2024 | stockhouse.comIncyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular LymphomaAugust 22, 2024 | DTI (Ad)3 dividend stocks to ownThe “Income Ace” Jack Carter just revealed his entire dividend strategy. Including 3 specific tickers to consider owning. And his “golden rules” for trading dividend stocks. These aren’t just theoretical rules, either. Jack revealed that the vast majority of his income capital is deployed in this straightforward portfolio of dividend stocks.August 13, 2024 | uk.finance.yahoo.comMorphoSys AG (MORD.XC)August 12, 2024 | sg.finance.yahoo.comMorphoSys AG (1MOR.MI)August 8, 2024 | markets.businessinsider.comRoyalty Pharma Reports Second Quarter 2024 ResultsAugust 6, 2024 | stockhouse.comXencor Reports Second Quarter 2024 Financial ResultsAugust 5, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Plunge in Monday TradingAugust 22, 2024 | DTI (Ad)3 dividend stocks to ownThe “Income Ace” Jack Carter just revealed his entire dividend strategy. Including 3 specific tickers to consider owning. And his “golden rules” for trading dividend stocks. These aren’t just theoretical rules, either. Jack revealed that the vast majority of his income capital is deployed in this straightforward portfolio of dividend stocks.July 25, 2024 | tmcnet.comEVPassport Announces Opening of East Coast Headquarters in Boston and Key Executive Appointments Amidst Rapid GrowthJuly 16, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG – MORJuly 15, 2024 | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MORJuly 8, 2024 | seekingalpha.comMorphoSys: Novartis Deal Is All But DoneJune 20, 2024 | businesswire.comMOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to ShareholdersJune 20, 2024 | businesswire.comMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority ShareholdersMay 28, 2024 | msn.comMonoclonal Antibody May Benefit Patients With Kidney Transplant RejectionMay 27, 2024 | msn.comNovartis releases Phase III data on its investigational oral therapy to treat chronic kidney diseaseMay 16, 2024 | finanznachrichten.deNovartis Pharma AG: Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cashSee More Headlines Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today8/22/2024Next Earnings (Confirmed)8/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MOR CUSIPN/A CIK1340243 Webwww.morphosys.com Phone(498) 989-9270Fax49-89-8992-7222Employees730Year FoundedN/APrice Target and Rating Average Stock Price Target$11.78 High Stock Price Target$18.25 Low Stock Price Target$4.75 Potential Upside/Downside-37.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,350,000.00 Net Margins-226.79% Pretax Margin-225.77% Return on Equity-694.31% Return on Assets-22.55% Debt Debt-to-Equity Ratio4.98 Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$238.28 million Price / Sales11.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book54.17Miscellaneous Outstanding Shares150,621,000Free Float150,546,000Market Cap$2.86 billion OptionableNot Optionable Beta1.20 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 59)Chairman of Management Board, MD & CEO Comp: $1.91MDr. Lucinda Crabtree Ph.D. (Age 45)CFO & Member of Management Board Comp: $764.53kMs. Charlotte Lohmann (Age 54)Chief Legal and Human Resources Officer & Member of Management Board Comp: $513.54kMr. Klaus De WallHead of Accounting & TaxDr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Julia Neugebauer Ph.D.Head of Investor RelationsDr. Barbara Krebs-Pohl Ph.D.Chief Business OfficerDr. Günter WellnhoferHead of Technical OperationsDr. Harald WatzkaHead of Alliance ManagementMs. Yen Ching ChuaHead of Clinical OperationsMore ExecutivesKey CompetitorsCatalentNYSE:CTLTQiagenNYSE:QGENLegend BiotechNASDAQ:LEGNVaxcyteNASDAQ:PCVXRoivant SciencesNASDAQ:ROIVView All CompetitorsInstitutional OwnershipTrium Capital LLPSold 11,700 shares on 8/6/2024Ownership: 0.000%Rhumbline AdvisersBought 785 shares on 8/1/2024Ownership: 0.003%Hennion & Walsh Asset Management Inc.Bought 7,644 shares on 7/20/2024Ownership: 0.083%GAMMA Investing LLCBought 931 shares on 7/2/2024Ownership: 0.002%Opaleye Management Inc.Sold 80,000 shares on 5/29/2024Ownership: 0.043%View All Institutional Transactions MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed this year? MorphoSys' stock was trading at $9.90 at the start of the year. Since then, MOR shares have increased by 91.5% and is now trading at $18.96. View the best growth stocks for 2024 here. What is Simon E. Moroney's approval rating as MorphoSys' CEO? 5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did MorphoSys IPO? MorphoSys (MOR) raised $200 million in an initial public offering on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers. Who are MorphoSys' major shareholders? Top institutional shareholders of MorphoSys include Hennion & Walsh Asset Management Inc. (0.08%), Rhumbline Advisers, GAMMA Investing LLC and Trium Capital LLP. How do I buy shares of MorphoSys? Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MOR) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
